Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Invested Capital (2020 - 2025)

Historic Invested Capital for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $379.2 million.

  • Cytek Biosciences' Invested Capital fell 193.25% to $379.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $379.2 million, marking a year-over-year decrease of 193.25%. This contributed to the annual value of $396.8 million for FY2024, which is 52.57% up from last year.
  • Cytek Biosciences' Invested Capital amounted to $379.2 million in Q3 2025, which was down 193.25% from $378.3 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Invested Capital peaked at $427.8 million during Q4 2022, and registered a low of -$11.0 million during Q2 2021.
  • For the 5-year period, Cytek Biosciences' Invested Capital averaged around $379.5 million, with its median value being $400.0 million (2021).
  • As far as peak fluctuations go, Cytek Biosciences' Invested Capital surged by 384264.0% in 2022, and later crashed by 835.75% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' Invested Capital stood at $405.4 million in 2021, then rose by 5.53% to $427.8 million in 2022, then fell by 7.74% to $394.7 million in 2023, then rose by 0.53% to $396.8 million in 2024, then fell by 4.43% to $379.2 million in 2025.
  • Its last three reported values are $379.2 million in Q3 2025, $378.3 million for Q2 2025, and $380.5 million during Q1 2025.